Antigen News and Research

RSS

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers.

18 Sep 2013

Three-gene biomarker can help determine treatment option for early prostate cancer

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.

13 Sep 2013

Researchers study potential role of two risk factors in preeclampsia

Although preeclampsia occurs in about 3 percent of pregnancies, it's still unforeseen in many cases. A report of new research, now in press at the Journal of Reproductive Immunology, documents how two distinct risk factors combine to affect the odds that a first-time mother could develop the sometimes life-threatening pregnancy complication.

11 Sep 2013

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Scientists from A*STAR's Singapore Immunology Network have discovered a new defense mechanism that the immune system utilises to combat infections. The team's discovery of how a novel protein unexpectedly activates an immune response shows how this mechanism can also be used to get rid of tumour cells.

11 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira, the world's leading provider of injectable drugs and infusion technologies, today announced the European Commission (EC) approval of Inflectra™ (infliximab), Europe's first biosimilar monoclonal antibody (mAb) therapy. Inflectra has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

Scientists develop strain of MERS-CoV that can be used as vaccine against disease

Scientists have developed a strain of the Middle East respiratory syndrome coronavirus (MERS-CoV) that could be used as a vaccine against the disease, according to a study to be published in mBio-, the online open-access journal of the American Society for Microbiology.

10 Sep 2013

Little STING could go long way in avoiding arthritis, type 1 diabetes, report researchers

A little STING could go a long way in helping treat or even avoid autoimmune diseases such as arthritis, type 1 diabetes and multiple sclerosis, researchers report.

10 Sep 2013

New technology to diagnose influenza quickly

A new technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs slams shut and sick people spread the virus to others, scientists reported here today. In a presentation at the 246th National Meeting & Exposition of the American Chemical Society (ACS), they described how it also could determine the specific strain of flu virus and help select the most effective drug for treatment.

10 Sep 2013

Nuclea Biotechnologies Acquires Wilex' U.S. Subsidiary

...

9 Sep 2013

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PharmAthene, Inc. announced today that new data from the Company's SparVax® next-generation anthrax vaccine program were presented in two separate oral presentations at the 2013 Bacillus – ACT international anthrax conference in Victoria, British Columbia, Canada.

7 Sep 2013

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced that it has commenced its Phase 3 clinical trial program for its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Approximately 3,000 participants will be enrolled in this pivotal program, which is comprised of cholera challenge, safety, and immunogenicity studies.

7 Sep 2013

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

"Hepatitis B virus infection causes infant fulminant hepatitis, and chronic HBV infection may progress to chronic liver disease and hepatocellular carcinoma. Taiwan launched a nationwide HBV immunization program for newborns in July 1984, which has successfully lowered the prevalence of chronic HBV carriers, incidence of HCC, and mortality of IFH in vaccinated birth cohorts. The mortality of CLD before and after HBV immunization has never been examined," write Chun-Ju Chiang, Ph.D., of National Taiwan University, Taipei, and colleagues.

4 Sep 2013

New recombinant antibody can recognize MSCs in umbilical cord blood

A new recombinant antibody can detect and isolate mesenchymal stem cells (MSCs), a nonembryonic source of stem cells with promising applications in tissue engineering, blood stem cell transplantation, and treatments for immune-mediated disorders.

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Biostatistician uses statistical and computer modeling for policy development in prostate cancer research

Ruth Etzioni, Ph.D., a biostatistician, is a member of the Public Health Sciences Division at Fred Hutchinson Cancer Research Center.

29 Aug 2013

Researchers suggest new therapeutic target for brain tumor

Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas — the most common form of brain tumor — suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.

28 Aug 2013

Researchers find specific protein in nearly all high-grade meningiomas

Johns Hopkins researchers say they have found a specific protein in nearly 100 percent of high-grade meningiomas -- the most common form of brain tumor -- suggesting a new target for therapies for a cancer that does not respond to current chemotherapy.

28 Aug 2013

Antigen News and Research

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Three-gene biomarker can help determine treatment option for early prostate cancer

Researchers study potential role of two risk factors in preeclampsia

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Roche Signs Up To $422.5M Collaboration With Inovio

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Scientists develop strain of MERS-CoV that can be used as vaccine against disease

Little STING could go long way in avoiding arthritis, type 1 diabetes, report researchers

New technology to diagnose influenza quickly

Nuclea Biotechnologies Acquires Wilex' U.S. Subsidiary

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

PaxVax commences phase 3 clinical trial for single-dose oral cholera vaccine candidate

Taiwan's HBV immunization program for newborns lowers chronic HBV carriers, incidence of HCC

New recombinant antibody can recognize MSCs in umbilical cord blood

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Biostatistician uses statistical and computer modeling for policy development in prostate cancer research

Researchers suggest new therapeutic target for brain tumor

Researchers find specific protein in nearly all high-grade meningiomas

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News